Nuchev Launches Kuci Range Nationally via Chemist Warehouse
Nuchev has inked a consignment-based distribution deal to launch the Kuci women’s health probiotic range nationally through Chemist Warehouse, marking a strategic expansion into women’s health.
- Exclusive national distribution deal for Kuci women’s health range
- Consignment model limits Nuchev’s inventory risk
- Kuci expands Nuchev’s portfolio beyond infant and functional nutrition
- Biomera retains product supply and brand investment responsibilities
- No minimum purchase commitments; revenue depends on consumer demand
Nuchev Moves into Women’s Health with Kuci Brand
Nuchev Limited (ASX:NUC) is broadening its product portfolio with an exclusive national rollout of the Kuci women’s health probiotic range through Chemist Warehouse. The deal, struck with Biomera Biotics, taps into the growing women’s health market by offering clinically researched probiotic products tailored to women’s changing health needs across life stages.
The Kuci range complements Nuchev’s existing infant nutrition, practitioner health, and functional nutrition offerings, presenting a new retail growth avenue. Chief Executive Nathan Cheong highlighted that the partnership leverages Nuchev’s existing sales and distribution infrastructure, aligning with the company’s focus on profitable growth through disciplined working capital management.
Consignment Model Mitigates Inventory Risk
Under the agreement, Biomera will supply Kuci products on a consignment basis, maintaining responsibility for product supply and brand investment. Nuchev will handle sales and distribution, earning a margin on products sold through Chemist Warehouse and other channels. This consignment approach limits Nuchev’s inventory and working capital exposure compared to traditional buy-and-sell models.
Notably, the agreement carries no minimum purchase commitments, meaning Nuchev’s financial upside depends on consumer demand and product sell-through. The company has not provided separate earnings guidance related to this deal, reflecting inherent uncertainty in near-term revenue contributions.
Related-Party Deal Approved by Non-Conflicted Directors
The distribution agreement involves Biomera, a related party to Nuchev through shared ownership structures. To manage conflicts of interest, directors with ties to Biomera abstained from the approval process, leaving non-conflicted directors to evaluate and endorse the commercial terms and strategic benefits.
This governance step underscores the company’s commitment to transparency and proper oversight despite the related-party nature of the deal.
Strategic Implications for Nuchev’s Growth
The Kuci rollout arrives as Nuchev seeks to diversify its revenue streams beyond its core Oli6® infant nutrition brand and health practitioner channels. Recent financials showed revenue growth but margin pressures and widening EBITDA losses, prompting a sharper focus on margin recovery and cash discipline. Adding a women’s health brand distributed through a major pharmacy chain could provide a valuable new revenue engine without significantly increasing inventory risk.
Bottom Line?
Nuchev’s consignment deal for Kuci opens a new growth front in women’s health while carefully managing working capital risk.
Questions in the middle?
- How quickly will Kuci gain traction in the competitive women’s health probiotic market?
- What margin contribution can Nuchev realistically expect given the consignment model and no purchase minimums?
- Will Nuchev pursue further related-party distribution deals or diversify supplier partnerships?
